AbCellera Biologics Past Earnings Performance
Past criteria checks 0/6
AbCellera Biologics's earnings have been declining at an average annual rate of -28.2%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been declining at an average rate of 49.4% per year.
Key information
-28.2%
Earnings growth rate
-29.8%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | -49.4% |
| Return on equity | -13.0% |
| Net Margin | -410.5% |
| Next Earnings Update | 06 Aug 2024 |
Recent past performance updates
Recent updates
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
May 29
AbCellera: Cash Providing Shelter From Market Weakness
May 16AbCellera: Victim Of Its Own Success
Feb 28AbCellera Biologics: Continuing To Expand Partnerships
Feb 13Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
Dec 05AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy
Oct 18AbCellera Biologics: I Was Wrong
Aug 20AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be
Aug 17AbCellera Biologics: A Buy At Current Prices
Aug 06Revenue & Expenses Breakdown
How AbCellera Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 36 | -147 | 77 | 0 |
| 31 Dec 23 | 38 | -146 | 75 | 0 |
| 30 Sep 23 | 50 | -129 | 72 | 0 |
| 30 Jun 23 | 145 | -74 | 71 | 0 |
| 31 Mar 23 | 181 | -50 | 69 | 0 |
| 31 Dec 22 | 485 | 159 | 67 | 0 |
| 30 Sep 22 | 603 | 248 | 66 | 0 |
| 30 Jun 22 | 507 | 200 | 61 | 0 |
| 31 Mar 22 | 489 | 205 | 56 | 0 |
| 31 Dec 21 | 375 | 153 | 49 | 0 |
| 30 Sep 21 | 444 | 177 | 40 | 0 |
| 30 Jun 21 | 448 | 197 | 31 | 0 |
| 31 Mar 21 | 431 | 203 | 21 | 0 |
| 31 Dec 20 | 233 | 85 | 16 | 0 |
| 30 Sep 20 | 28 | 0 | 9 | 0 |
| 30 Jun 20 | 23 | 2 | 7 | 0 |
| 31 Mar 20 | 14 | -3 | 5 | 0 |
| 31 Dec 19 | 12 | -2 | 4 | 0 |
| 31 Dec 18 | 9 | 0 | 3 | 0 |
Quality Earnings: ABCL is currently unprofitable.
Growing Profit Margin: ABCL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABCL is unprofitable, and losses have increased over the past 5 years at a rate of 28.2% per year.
Accelerating Growth: Unable to compare ABCL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABCL is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.5%).
Return on Equity
High ROE: ABCL has a negative Return on Equity (-13%), as it is currently unprofitable.